Literature DB >> 30319985

Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence.

Chiara Carone1, Andrea Olivani2, Raffaele Dalla Valle3, Roberta Manuguerra4, Enrico Maria Silini4, Tommaso Trenti1, Gabriele Missale2, Elisabetta Cariani1.   

Abstract

BACKGROUND: The antitumor immune response may play a major role in the clinical outcome of hepatocellular carcinoma (HCC). We characterized the liver immune microenvironment by direct hybridization of RNA extracted from HCC and nontumorous tissues.
METHODS: RNA was extracted from frozen liver tissue samples of HCC (T; n = 30) and nontumorous tissues (NT; n = 33) obtained from 38 patients. Matched samples were available for 25 patients. The immune gene expression profile was analyzed with the nCounter GX Human Immunology v2 system (NanoString Technologies), which detects the expression levels of 579 immune response-related genes simultaneously.
RESULTS: Since the immune gene expression profile of T and NT tissues was significantly different, the prognostic relevance of the liver immune microenvironment was evaluated in the T and NT samples separately. Unsupervised clustering detected two main clusters of immune gene expression both in T and in NT liver samples. In both cases, the expression clusters identified groups of patients with a significantly different median time to HCC recurrence (TTR) but similar overall survival. Based on T tissue, two groups with median TTR of 19 and 127 months, respectively, were detected (p < 0.005). Expression of genes related to T-cell activation was associated with longer TTR. The analysis of NT tissue discriminated subsets of patients with median TTR of 22 and 68 months (p < 0.05). In contrast to T tissue, a predominant inflammatory immune environment was associated with shorter TTR.
CONCLUSIONS: Immune gene expression profiles predictive of TTR could be identified both in HCC and in adjacent cirrhotic tissues. Longer TTR was associated with overexpression in T tissue and downregulation in NT tissue of the immune response and of inflammation-related genes.

Entities:  

Keywords:  Hepatocellular carcinoma; Immune microenvironment; Prognosis; Recurrence; T lymphocytes

Year:  2018        PMID: 30319985      PMCID: PMC6167723          DOI: 10.1159/000486764

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  52 in total

Review 1.  NFAT proteins: key regulators of T-cell development and function.

Authors:  Fernando Macian
Journal:  Nat Rev Immunol       Date:  2005-06       Impact factor: 53.106

2.  Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Salvatore Petta; Marco Barbara; Simona Attardo; Laura Bucci; Fabio Farinati; Edoardo G Giannini; Giulia Negrini; Francesca Ciccarese; Gian Lodovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Rodolfo Sacco; Roberto Virdone; Fabio Marra; Andrea Mega; Filomena Morisco; Luisa Benvegnù; Antonio Gasbarrini; Gianluca Svegliati-Baroni; Francesco Giuseppe Foschi; Andrea Olivani; Alberto Masotto; Gerardo Nardone; Antonio Colecchia; Marcello Persico; Antonio Craxì; Franco Trevisani; Calogero Cammà
Journal:  J Hepatol       Date:  2017-02-10       Impact factor: 25.083

3.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

4.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Authors:  Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

5.  Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.

Authors:  Yunfei Yuan; Jianping Wang; Jinqing Li; Li Wang; Meixiang Li; Zuli Yang; Changqing Zhang; Jia Le Dai
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

6.  IL-10 elicits IFNγ-dependent tumor immune surveillance.

Authors:  John B Mumm; Jan Emmerich; Xueqing Zhang; Ivan Chan; Lingling Wu; Smita Mauze; Steven Blaisdell; Beth Basham; Jie Dai; Jeff Grein; Catherine Sheppard; Kyu Hong; Collette Cutler; Scott Turner; Drake LaFace; Melanie Kleinschek; Michael Judo; Gulesi Ayanoglu; John Langowski; Danling Gu; Brittany Paporello; Erin Murphy; Venkataraman Sriram; Saraswathi Naravula; Bela Desai; Satya Medicherla; Wolfgang Seghezzi; Terrill McClanahan; Susan Cannon-Carlson; Amy M Beebe; Martin Oft
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

7.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

8.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.

Authors:  Damian Szklarczyk; John H Morris; Helen Cook; Michael Kuhn; Stefan Wyder; Milan Simonovic; Alberto Santos; Nadezhda T Doncheva; Alexander Roth; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2016-10-18       Impact factor: 16.971

View more
  11 in total

1.  Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-04-29       Impact factor: 11.740

2.  Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-07-09       Impact factor: 11.740

3.  Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.

Authors:  Zhi-Qiang Hu; Hao-Yang Xin; Chu-Bin Luo; Jia Li; Zheng-Jun Zhou; Ji-Xue Zou; Shao-Lai Zhou
Journal:  Cancer Immunol Immunother       Date:  2020-08-06       Impact factor: 6.968

4.  Development and validation of a prognostic and immunotherapeutically relevant model in hepatocellular carcinoma.

Authors:  Yu Wang; Yanting Xie; Junyong Ma; Yizhou Wang; Renyan Gong
Journal:  Ann Transl Med       Date:  2020-09

5.  Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.

Authors:  Yanan Peng; Chang Liu; Mengting Li; Wenjie Li; Mengna Zhang; Xiang Jiang; Ying Chang; Lan Liu; Fan Wang; Qiu Zhao
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

6.  Prognostic value of a novel glycolysis-related gene expression signature for gastrointestinal cancer in the Asian population.

Authors:  Rong Xia; Hua Tang; Jiemiao Shen; Shuyu Xu; Yinyin Liang; Yuxin Zhang; Xing Gong; Yue Min; Di Zhang; Chenzhe Tao; Shoulin Wang; Yi Zhang; Jinyou Yang; Chao Wang
Journal:  Cancer Cell Int       Date:  2021-03-04       Impact factor: 5.722

7.  Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.

Authors:  Zaoqu Liu; Dechao Jiao; Long Liu; Xueliang Zhou; Yuan Yao; Zhaonan Li; Jing Li; Jianjian Chen; Qinyu Lei; Xinwei Han
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

8.  N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.

Authors:  Shen Shen; Jingya Yan; Yize Zhang; Zihui Dong; Jiyuan Xing; Yuting He
Journal:  Ann Transl Med       Date:  2021-01

Review 9.  Role of spleen tyrosine kinase in liver diseases.

Authors:  Dhadhang Wahyu Kurniawan; Gert Storm; Jai Prakash; Ruchi Bansal
Journal:  World J Gastroenterol       Date:  2020-03-14       Impact factor: 5.742

10.  Development of an immune-related prognostic index associated with hepatocellular carcinoma.

Authors:  Bo Hu; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Aging (Albany NY)       Date:  2020-03-19       Impact factor: 5.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.